This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BERKELEY, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the company's Senior Vice President, Research and Development and Chief Medical Officer, is scheduled to present at JMP Securities 2013 Healthcare Conference on July 9, 2013 at 3:30 p.m. ET.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at
http://investors.xoma.com/events.cfm . An archived version of the webcast will be available via replay for 30 days following the presentation.
About XOMA Corporation
XOMA is a biotechnology company focused on advancing its portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research. Its antibody research and development centers on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product candidate, gevokizumab (IL-1 beta modulating antibody), with SERVIER through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific discoveries led to establishment of the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs), which could have a major effect on the treatment of insulin-related diseases.
More detailed information can be found at
CONTACT: Company and Investor Contacts:
The Oratorium Group, LLC